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TuberculosisA B S T R A C T
Objective/background: The search for new vaccines more efficacious than bacille Calmette–
Gue´rin for tuberculosis prevention is of paramount importance for the control of the dis-
ease. The expression of Mycobacterium tuberculosis antigens in Mycobacterium smegmatis is
one of the current strategies for the development of new-generation vaccines against
tuberculosis. The objective of this study was to evaluate the immunogenicity in mice of
M. smegmatis expressing epitopes from Ag85B antigen.
Methods: M. smegmatis expressing three T cell epitopes fromM. tuberculosis Ag85B (P21, P26,
and P53) was constructed (rMs064). rMs064 was used to immunize BALB/C mice for
immunogenicity evaluation. The present study investigates the capacity of rMs064 to
induce specific cellular and humoral immune responses against the expressed epitopes.
Cytokine production upon stimulation with Ag85B peptides and specific total immunoglob-
ulin G and immunoglobulin G subclasses were determined.
Results: The results showed a significant production of interleukin-12 and interleukin-23
when splenocytes were stimulated with P21, P26, and P53 peptides, and interferon-c after
stimulation with P21 in animals immunized with rMs064 compared with controls. The total
immunoglobulin G and its subclasses showed significant increases against the Ag85B epi-
topes in the sera of rMs064-immunized mice compared with the control groups.
Conclusion: The results of this study support the future evaluation of rMs064 as a vaccine
candidate against tuberculosis in challenge experiments.
 2015 Production and hosting by Elsevier Ltd. on behalf of Asian African Society for
Mycobacteriology.Introduction
Tuberculosis (TB) remains one of the primary infectious-
disease burdens in most part of the world [1,2]. One-third ofthe world’s population is already infected with Mycobacterium
tuberculosis, in which 10% of infected individuals carry a life-
time risk of developing the disease [1]. The use of the bacille
Calmette–Gue´rin (BCG) vaccine shows variable efficacy
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the severe forms of the disease in children [3,4]. The develop-
ment of an effective vaccine has been highlighted as one of
the most effective means toward the control of TB [2].
Mycobacterium smegmatis is a nonpathogenic, rapidly grow-
ing, and commensal strain of Mycobacterium species. The
most important advantage ofM. smegmatis as a vaccine vector
is due to the genetic and structural homology of this strain
with M. tuberculosis [5,6]. M. smegmatis also has similarities
in cell-wall lipid moiety, and shares the same mechanisms
of cell-wall synthesis with those of M. tuberculosis [6]. In addi-
tion, M. smegmatis is superior in activating and inducing the
maturation of dendritic cells (DCs) compared to BCG [7]. In
terms of activating adaptive immunity, M. smegmatis is a
strong inducer of effector and memory T cells [8,9]. Autop-
hagy has been described as an important mechanism in the
defense against TB; in this regard, a recent study has showed
that the lipid components of M. smegmatis have the capacity
to initiate and modulate autophagy in murine macrophages
independent of mammalian-target-of-rapamycin signaling
pathway [10].
Experimental vaccines based on the cell-wall components
of M. smegmatis elicited cross-reactive responses against
M. tuberculosis antigens in mice [11–13]. RecombinantM. smeg-
matis expressing the 6-kDa early secreted antigen (ESAT-6)
and culture-filtrate protein (CFP)-10 has been shown to reduce
the bacterial load in the lungs of immunized mice challenged
with a virulent M. tuberculosis strain [14]. These antecedents
support the interest in the evaluation ofM. smegmatis as a live
vaccine vector for the expression of recombinant proteins, in
particular those fromM. tuberculosis as a potential strategy for
the development of new-generation vaccines against TB.
Ag85 complex consists of highly homologous 30–32 kDa
CFPs (85A, 85B, and 85C) ofM. tuberculosis [15]. These antigens
are associated with mycolyl-transferase activity in vitro, and
catalyze the synthesis of the glycolipid of mycobacterial cell
wall [16]. The Ag85 components, also known as fibronectin-
binding proteins, interact with fibronectin at a specific
fibronectin-binding motif of the host cell [17]. Fibronectin
plays an important role in bacteria–host interactions by
binding with microbial surface components, leading to the
initiation of infection [18]. Ag85B has been shown to promote
excellent immunogenicity in experimental animal models,
and it is essential in the induction of cellular and humoral
immunity [19,20].
The reports related with the potential importance of the
humoral immune response in protection against TB have
opened a new avenue in the development of new-
generation vaccines against TB [21,22]. Ag85B is considered
among the M. tuberculosis antigens, which can potentially
induce protective antibodies based on reports of a better
prognosis in TB patients with circulating immunoglobulin
G (IgG) antibodies against M. tuberculosis Ag85 complex [23].
Taking into consideration these antecedents, the possibility
to express Ag85B epitopes in M. smegmatis to induce protective
immune responses against TB is an interesting possibility; in
this study, epitopes fromAg85B antigen (P21, P26, and P53) were
cloned into M. smegmatis (rMs064), and the cellular and
humoral immunogenicity was evaluated in mice.Materials and methods
Construction of rMs064
Strain
M. smegmatismc2155 strain was used. Cultures were grown in
Middlebrook 7H9 supplemented with 0.2% (volume/volume
[v/v]) glycerol, 0.5% (v/v) Tween 20, and 10% (v/v) oleic–albu
min–dextrose–catalase for 48 h with agitation (200 rpm)
at 37 C. The purity of the culture was evaluated by Ziehl–
Neelsen staining [24].
Selection of Ag85B epitopes
Epitopes P21101–115 (LTSELPQWLSANRAV), P26126–140 (SMAGS-
SAMILAAYHP), and P53261–275 (THSWEYWGAQLNAMK) were
selected from M. tuberculosis Ag85B protein based on previous
reports [25], and the presence of B epitopes in these
sequences was demonstrated using the ABCpred Bioinfor-
matics prediction tool (http://www.imtech.res.in/raghava/
bcepred/) [26].
Genetic transformation
A multi-epitope construct including P21, P26, and P53 epi-
topes from Ag85B with codon usage optimized for mycobacte-
ria was synthesized by Geneart (Bavaria, Germany). The DNA
fragment was fused to the MTB8.4 protein gene, into the
pNMN012 mycobacterial shuttle plasmid under the control
of the M. tuberculosis Hsp65 antigen promoter, followed by
the M. tuberculosis MPT63 signal sequence. The genetic trans-
formation of M. smegmatis was carried out by electroporation
[27]. A negative control strain was obtained by the transfor-
mation of M. smegmatis with pNMN012 (rMs012). The expres-
sion of the epitopes was determined by Western blotting
using anti-6 His antibodies (Abcam, Cambridge, UK).
Peptides
Peptides corresponding with the Ag85B epitopes P21, P26, and
P53 were commercially synthesized (1st BASE Laboratories,
Singapore Science Park II, Singapore).
Evaluation of cellular and humoral Immunogenicity
Immunization schedule
Male BALB/c mice (6–8 weeks), supplied by the Animal
Research and Service Centre, Universiti Sains Malaysia, were
used in the experiments. All procedures were carried out
according to the standard international regulations and
guidelines of laboratory animal experimentation [28], and
approved by the Ethical Committee for Experimentation in
Animals of the Universiti Sains Malaysia. Three groups of ani-
mals (n = 5 per group) were inoculated subcutaneously with
2  106 CFU of rMs064, rMs012 (both strains were suspended
in 100 lL of phosphate-buffered saline [PBS]), or PBS alone.
Two doses were administered in a 2-week interval. Blood
samples were taken at 35 days after the first immunization.
The blood was centrifuged and the serum stored at 20 C
until use. Subsequently, the mice were sacrificed, and the
spleens were aseptically removed to assess the cellular
immune response.
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The splenocytes from immunized mice were cultured
(2  105 cells/mL) in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, USA) supplemented with 10% heat-
inactivated fetal calf serum, 100 U/mL penicillin, and 100 lg/
mL streptomycin at 37 C. The cultures were stimulated with
10 lg/mL of P21, P26, and P53 peptides. Following the 72-h
incubation, cell-free supernatant was harvested and assayed
for the presence of interferon (IFN)-c, interleukin (IL)-12 (IL-
12p70), IL-23, and IL-4 by enzyme-linked immunosorbent
assay (eBioscience, San Diego, USA) according to the manu-
facturer’s instructions.
Determination of specific total IgG and IgG subclass antibodies
The specific total IgG and IgG subclass levels were determined
by enzyme-linked immunosorbent assay against P21, P26, and
P53 peptides. Briefly, 96-well MaxiSorp plates (Nunc,
Rochester, USA) were coated with each peptide (1 lg/mL) in
coating buffer, incubated overnight at 4 C, washed five times
with PBS containing 0.1% Tween 20, and blocked with
blocking buffer (Roche, Mannheim, Germany) for 1 h at 37 
C. The plates were incubated with the mice sera (in
triplicates) at a dilution of 1:50, and incubated for 2 h at 37 
C. The plates were washed five times, and horseradish-perox
idase-conjugated goat antimouse IgG or anti subclass IgG1,
IgG2a, and IgG2b (Dako, Carpinteria, CA, USA) were added at
1:1000 dilution for 1 h at 37 C. The enzyme reaction was
developed with 2,20-azino-di(3-ethyl-benzothiazolesulfonate)
(ABTS; Roche). The reaction was stopped after 30 min
with 2 N H2SO4 and the optical density determined with a
microplate reader (Tecan, San Jose, USA) at 405 nm.
Statistical analysis
The results were analyzed using one-way analysis-of-variance
test and the differences between groups were determined by
Tukey’s post-test. A p value was considered significant.
Results
The replicative plasmid pNMN064 was electroporated into M.
smegmatis mc2 155 to produce rMs064, and the expression ofFig. 1 – Expression of 85B epitopes in Mycobacterium
smegmatis by Western blotting. (1) Prestained protein
marker; (2) rMs012 cell lysate; (3) rMs064 cell lysate. SDS–
PAGE = sodium dodecyl sulfate–polyacrylamide gel
electrophoresis.the recombinant protein was detected as a 22-kDa band by
Western blotting (Fig. 1).
To assess the induction of specific cellular responses, the
splenocytes obtained from mice immunized with rMs012
and rMs064 were stimulated with P21, P26, and P53 peptides.
The production of IFN-c, IL-12, IL-23, and IL-4 cytokines was
then evaluated. A significant IL-12 production was observed
in P21-, P26-, and P53-stimulated splenocytes in rMs064-
immunized mice compared with the other groups (Fig. 2A).
A significant increase in the production of IL-23 upon stim-
ulation with all three epitopes was observed in rMs064-
immunized mice (Fig. 2B).
Splenocytes from rMs064-immunized mice showed signif-
icant highest production of IFN-c when stimulated with P21
peptide compared to the other groups (Fig. 2C).
Regarding IL-4, therewas no increase of this cytokine upon
stimulation with any of the epitopes (data not shown).
A significant increase was observed in the level of total IgG
against all Ag85B epitopes after the immunization of mice
with rMs064 compared to the other groups (Fig. 3A). Enhanced
levels of specific IgG1 subclass were detected against P21, P26,
and P53 epitopes of Ag85B (Fig. 3B). However, specific IgG2a
antibodies showed a significant increase only against P26 epi-
tope (Fig. 3C), while specific IgG2b production was signifi-
cantly increased against P53 (Fig. 3D). The subclass
responses against the individual Ag85B epitopes indicate that
rMs064 stimulated both the T helper cell type 1 (Th1)- and T
helper cell type 2-associated IgG subclasses (IgG2a, IgG2b,
and IgG1, respectively).Discussion
Ag85B epitopes designated as P21, P26, and P53 were success-
fully cloned into pNMN012 vector and expressed in M. smeg-
matis. These three Ag85B epitopes overlapped with regions
of the Ag85B protein recognized by guinea pigs and purified-
protein-derivative-positive individuals [25]. It has been
demonstrated that these epitopes were immunogenic in mice
when expressed in BCG [29], and contain predicted B cell
epitopes as determined with the ABCpred Bioinformatics pre-
diction tool (data not shown), which support their evaluation
as vaccine candidates.
M. smegmatis has several advantages, which make it an
attractive carrier for the expression of M. tuberculosis anti-
gens/epitopes. M. smegmatis is a fast grower, nonpathogenic,
has genetic and antigenic homology with M. tuberculosis,
and, as such, has the possibility to express M. tuberculosis
antigens in their native conformation. Furthermore, induc-
tion of DCmaturation with increased expression of major his-
tocompatibility complex class I and class II molecules,
induction of autophagy, and strong generation of effector
and memory T cells have been previously proposed [5–10].
M. smegmatis overexpressing whole Ag85B protein protects
mice in a challenge model with M. tuberculosis [30]. The same
effect was obtained in guinea pigs with recombinant BCG
overexpressing Ag85B, and this vaccine candidate showed
cross-protective responses against Mycobacterium leprae
[31,32]. The expression of a fusion protein of Ag85B and
































































































































Fig. 2 – Production of (A) interleukin-12 (IL-12p70), (B) interleukin-23, and (C) interferon-c against P21, P26, and P53. BALB/c
mice (n = 5 per group) were immunized with either phosphate-buffered saline, rMs012, or rMs064. Results are presented as
mean ± standard error of the mean. IFN = interferon; IL = interleukin; PBS = phosphate-buffered saline. *p < .05. **p < .01.
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dates expressing Ag85C, MPT51, and HspX (designated as
mc2 CMX) also induced both specific IgG2a and IgG1, and pro-
tect mice against M. tuberculosis [34].
The capacity of M. smegmatis expressing epitopes of Ag85B
to stimulate specific cellular immune response was demon-
strated by the production of IL2, IL23, and IFN-c after the stim-
ulation of splenocytes from rMs064-immunized mice.
IL-12 is produced by phagocytic cells and plays a key role in
host defense against M. tuberculosis infection [35]. The
production of IL-12p70, cytokine made up of p35 and p40
heterodimer chains, is mainly produced upon the phagocyto-
sis of M. tuberculosis [36]. IL-12 mediates the activation and
development of Th1 CD4 and CD8 T lymphocytes [37]. IL-12
exerts its protective roles against mycobacterial infection
mainly through the induction of IFN-c; thus, it acts as a link
between the innate and adaptive host response [38].
IL-23 is produced by activated monocytes, macrophages,
and DCs in response to mycobacterial infection, and is
considered an important cytokine for the protection againstM. tuberculosis after natural infection or vaccination [39,40].
The synergistic action of IL-12 and IL-23 promotes the recruit-
ment of antigen-specific CD4+ T cells in the draining lymph
nodes of M. tuberculosis-infected lungs [41]. Mice deficient in
both IL-12- and IL-23-secreted cytokines are susceptible to
infection with M. tuberculosis [36]. Other groups expressing a
fusion protein of heparin-binding hemagglutinin and human
IL-12 have reported prophylactic and/or therapeutic effect
against TB in mice [42]. The expression of IL-12 and gran-
ulysin in M. smegmatis produced a therapeutic effect against
TB in a model of infection in mice [43].
IFN-c is a dominant cytokine involved in antigen-specific T
cell immunity in response toM. tuberculosis infection [44]. The
importance of IFN-c and tumor necrosis factor-a as major
cytokines in mycobacterial infection is proven by the activa-
tion, under the influence of these cytokines, of the inducible
form of nitric oxide synthase and the production of reactive
nitrogen intermediates in murine macrophages, which is a
potent antimycobacterial effector mechanism [45]. Wang

































































































































































Fig. 3 – Enzyme-linked immunosorbent assay. (A) Total immunoglobulin G, (B) IgG1, (C) IgG2a, and (D) IgG2b response against
P21, P26, and P53. BALB/c mice (n = 5 per group) immunized with either phosphate-buffered saline, rMs012, or rMs064.
Results are presented as mean ± standard error of the mean. IgG = immunoglobulin G; PBS = phosphate-buffered saline.
*p < .05.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 7 –1 3 11C57BL/6 mice immunized with rMs expressing Ag85B-ESAT-6
fusion protein.
The humoral immunogenicity of the Ag85B epitopes
expressed in rMs was evident in the study of total IgG and
subclasses.
The induction of specific antibodies has been reported fol-
lowing immunization with rMs expressing a fusion protein of
the ESAT-6 and CFP-10 proteins fromM. tuberculosis [14]. It has
been reported that antigen Ag85B is highly expressed during
mycobacterial multiplication, as indicated by messenger
RNA copy number in mouse lung tissue infected with virulent
M. tuberculosis [46]. In this regard, the induction of specific
humoral responses recognizing Ag85B epitopes after the
immunization with rMs064 could be an important considera-
tion according to the potential role of antibodies in the protec-
tion against TB [47–49].It has been reported that specific antibodies against M.
tuberculosis antigens could contribute to the protection by
different mechanisms, among them interference with
mycobacterial adhesion, toxin neutralization, growth inhibi-
tion, opsonization, agglutination of the pathogen, enhance-
ment of cytokine release, complement activation, promotion
of phagosome–lysosome fusion, activation of cell-mediated
immunity, antibody-dependent cellular cytotoxicity, and
enhancement of antigen presentation [50,51].
Proteins of the Ag85 complex, including Ag85B, have enzy-
matic mycolyl-transferase activity related with the biogenesis
of cord factor, and bind to fibronectin and elastin, which are
associated with the survival and virulence of M. tuberculosis
[52]. In this regard, the elicitation of antibodies against
epitopes of Ag85B could interfere with important functions
of M. tuberculosis. It is important to note that epitope P53
12 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 7 –1 3contains an essential amino acid for the mycolyl-transferase
enzymatic activity [52].
The elicitation of humoral cross-reactive immune
responses against M. tuberculosis has been reported with
proteoliposomes and liposomes obtained from M. smegmatis
[11–13]. Liposomes containing lipids of M. smegmatis induced
protective immunity against M. tuberculosis in mice [53].
Considering these antecedents, the specific humoral immune
response induced by rMs064 against the Ag85B epitopes
could be reinforced by additional responses elicited by other
cross-reactive components of the carrier strain.
Conclusion
The demonstration of the cellular and humoral immuno-
genicity of rMs064 expressing selected epitopes from Ag85B
stimulating Th1 immune responses supports the further eval-
uation of this vaccine candidate in challenge experiments
with M. tuberculosis in mice.
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